The fact is that the immunodiagnostic model can distinguish 77.1% of HCC patients with AFP‐negative group, which suggests that the immunodiagnostic model can be used as a supplemental biomarker for detecting the AFP‐negative patients as the one previously identified [10]. The gene discussed is AFP; the disease is hepatocellular carcinoma.